Turkish Journal of Gastroenterology
Original Article

Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer

1.

Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey

2.

Department of Medical Genetics, Pamukkale University Faculty of Medicine, Denizli, Turkey

Turk J Gastroenterol 2022; 33: 696-703
DOI: 10.5152/tjg.2022.21829
Read: 876 Downloads: 453 Published: 11 May 2022

Background: First-line treatments for metastatic pancreatic cancer are chemotherapy regimens consisting of 5-fluorouracil or gemcitabine; however, there are no biomarkers to help determine which patients might benefit from which treatment regimens. We aimed to show that microRNAs let-7c and 7d can be used as independent predictive biomarkers for metastatic pancreatic cancer.

Methods: A total of 55 patients who had first-line chemotherapy with FOLFIRINOX or gemcitabine+capecitabine were included. Patients were divided into groups based on let-7c and let-7d levels and chemotherapy treatment as let-7c-7d high FOLFIRINOX, let7c-7d high gemcitabine+capecitabine, let-7c-7d low FOLFIRINOX, and let-7c-7d low gemcitabine+capecitabine. Blood samples were taken from patients before chemotherapy for microRNA let-7c and 7d analysis. MicroRNA isolation was performed using a miRNeasy Serum/Plasma Kit and identified using spectrophotometric measurements. After isolation, microRNA was converted to cDNA using a microRNA cDNA Synthesis Kit with poly (A) polymerase tailing. The expression of microRNA was examined using quantitative real-time polymerase chain reaction.

Results: The overall survival of patients who received FOLFIRINOX treatment with a high let-7c-7d level was statistically significantly longer than those who received gemcitabine+capecitabine with a high let-7c-7d level. In addition, patients with low let-7c expression receiving FOLFIRINOX progressed significantly 2.104 times earlier than patients with high let-7c expression receiving FOLFIRINOX.

Conclusion: The serum MicroRNA let-7c level was found to be an independent predictive biomarker in the FOLFIRINOX treatment group.

Cite this article as: Demiray AG, Demiray A, Yaren A, et al. Evaluation of serum microRNA let-7c and let-7d as predictive biomarkers for metastatic pancreatic cancer. Turk J Gastroenterol. 2022;33(8):696-703.

Files
EISSN 2148-5607